Company ProfilePremium

Megachem Limited

Company Profile Analysis

Ticker: 5DS.SI

ESOMAR 23 Corporate BadgeISO Certifications Badge
Megachem Limited - Company showcase

Year Founded & Workforce

1988

258 Employees

Megachem Limited logo

Megachem Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Megachem Limited Overview

Megachem is a small-cap Singapore specialty chemicals distributor. It sits between global chemical producers and more than 2,000 industrial customers, mostly multinationals, across Asia, Europe, the Middle East and Australia. It carries over 1,000 types and grades of specialty chemicals. Revenue is spread across coatings and polymers, surface technology, biotech/life sciences, advanced polymer composites and resources/oil and gas. A small contract-manufacturing and custom-blending arm (about 3% of revenue) supports the distribution business. The group has its own warehousing and blending infrastructure in Singapore, offices in 12 countries and a 36.19% stake in its SET-listed Thai associate. Japanese trading house Chori owns 29.99%. Revenue has stayed between S$123m and S$144m since 2021. Margins are thin and cyclical, and working-capital needs are high. The 2023 warehouse fire, now rebuilt, distorted profits from FY2023 to FY2025 and also forced the first capex cycle in more than a decade.


Company's own description

Megachem's filings describe it as a one-stop specialty chemical solutions provider, established in 1988. It provides integrated value-added services, including distribution and contract manufacturing of specialty chemicals, to meet customer requirements. The company says it distributes over 1,000 types and grades of specialty chemicals to more than 2,000 industrial customers, mostly well-known multinationals. It names its end-industries as water treatment, metal finishing, construction, oil and gas, food, beverage, flavours, fragrance, pharmaceuticals, polymers, coatings, electronics, rubber and plastics (Source: H1 2026 news release, 13 Aug 2026; FY2024 news release, 20 Feb 2025). The interim financial statements give its principal activities as trading in chemicals and chemical-related products, contract manufacturing of chemicals, and investment holding (H1 2026 condensed interim FS, Note 1.1).

Business model and value-chain position

Value chain stepWhat Megachem does
PurchaseGlobal sourcing network across China, Europe, Japan, the US and India. Sole-distributor appointments from several principals (the principals are not named).
StoreOwn warehousing in Singapore, including the rebuilt Major Hazard Installation (MHI)-compliant warehouse at 132 Pioneer Road, which received its Temporary Occupation Permit in June 2026. Third-party warehouses are also used.
Vendor-managed inventory (VMI) and just-in-time deliveryHolds stock near customer production sites and delivers on demand.
TransportLogistics coordination.
Custom blending / contract manufacturingMixing and blending to customer formulations, repackaging from bulk to smaller packs, filling, packaging and labelling.
Auxiliary servicesRepacking, relabelling, lab analysis.
Technical supportDedicated application laboratories.

Megachem is a third-party distributor in the middle of the chemical value chain, between producers and chemical users. The company's own business-model graphic (FY2025 results presentation; AR2024 p.11) lists these value-adding steps:

Revenue model

Revenue typeFY2025 SGD Mn% of totalNature
Distribution activity (sale of goods)121.197.4Margin on resale of third-party specialty chemicals. Transactional, spot and repeat orders.
Manufacturing activity (mainly custom-blending fees)3.32.6Service and toll fees. The company notes that manufacturing revenue consists mainly of custom-blending service fees.
Subscription / licensing00—

Sources: FY2025 results presentation; H1 2026 condensed interim FS, Review of Performance (half-year distribution of S$62.3m in H1 2025 and S$58.8m in H2 2025; manufacturing of S$1.7m and S$1.5m).

Customer types and end-markets

Industry clusterSub-applications (company list)Share of FY2025 sales
Performance Coatings & PolymersPaints and inks, polymerisation, adhesives, construction, textiles32%
Surface TechnologyElectronics, metal finishing, industrial cleaning, water treatment, pulp and paper27%
BiotechF&B, pharmaceuticals, nutraceuticals, cosmeceuticals, agriculture/feed, flavours and fragrances, homecare, photography21%
Advanced Polymer CompositesRubber, plastics, polyurethane, polyester12%
Resources / Oil & GasMining, oleochemicals, petrochemicals, lubricants and grease, oil field/refinery8%

Customers: more than 2,000 industrial customers, which the company says are mainly multinationals. No single-customer concentration is disclosed. The risk section states there is no significant concentration of credit risk (H1 2026 FS, Risks).

End-market mix, FY2025: (FY2025 results presentation, "Sales Breakdown by Industry Coverage"):

Independent characterisation

Megachem is a sub-scale, Asia-centric, multi-principal specialty distributor. Its economics resemble a working-capital-intensive trading business, not a specialty producer. Gross margins sit at 24–26% in normal years, and EBITDA margins were 5–9% outside the fire year. Inventory takes about 115–170 days to turn, depending on the measure. The edge it claims (breadth of product range, VMI/JIT, sole distributorships, custom blending) is real but narrow. Earnings track chemical price cycles closely, as the FY2021–22 boom and the 2023 destocking slump show. Ownership is tightly held: the founder plus Chori control about two-thirds of the shares. This limits liquidity and takeover optionality, but it also shields a conservative, dividend-paying management culture. The 2023 fire and the rebuild dominated reported results until H1 2026. With the rebuilt warehouse now operating, the main near-term investment question is whether lower third-party warehousing costs (S$3.3–3.4m a year in FY2024–25) can lift margins in a structural way.

Strategy

Stated strategy themes

  • Growth formula ("(CHemical)+Re(Action)2: for-Gr{OW}th"), AR2024: growth is built around three pillars — geographic network, product offerings and industry coverage. These are reinforced by supply-chain infrastructure and close customer and supplier relationships.

Two-pillar business model, AR2024 Risk Management: distribution and contract manufacturing are positioned as the twin growth engines. Diversification across markets, customers, products and suppliers is described as the core resilience strategy.

  • FY2026 "Unlocking our Potential" pillars, FY2025 results presentation:

    • High-growth markets: ASEAN countries such as Malaysia, Indonesia and Vietnam. The rationale given is tariff advantage, lower costs, a young population and a growing middle class, and rising FDI and production output.

    • High-growth industries: electronics, automotive, life sciences and materials science. This includes specialty chemicals for lightweight materials in EVs, electronics and robotics, and life-science chemicals driven by global ageing.

    • Management notes that China, the EU, ASEAN and India together account for about half of global manufacturing output and that Megachem is present in all four.

Operating priorities: prudent inventory management; operational and financial discipline; a shift towards specialty (rather than commodity) chemicals for margin stability (H1 2026 Prospects).

Strategic initiatives (last 24 months)

InitiativeStatus / detailSource
Warehouse rebuild at 132 Pioneer RoadBudget about S$19m (S$16.2m construction). Funded by insurance, bank loans and internal funds. Temporary Occupation Permit June 2026. Designed for safety, MHI compliance and environmental performance. Capacity of more than 5,000 pallets; target about 70% of storage in-house.AR2024; H1 2026 news release; The Edge (Aug 2025, Feb 2026)
Warehouse cost reductionMoving inventory back from third-party warehouses is expected to significantly reduce storage costs (third-party storage was S$3.4m in FY2024 and S$3.3m in FY2025).H1 2026 news release
Buy-out of minority interestsUK 85%→97% (Mar 2024); Megachem Raya group 74%→83% (Nov 2024)AR2024
EV materials exposure: JIOS AerogelUS$1m preference-share investment by Megachem plus US$2m by Megachem Thailand. JIOS has a pilot plant in Singapore and reported a thermal-blade supply contract with an automaker.2026 AGM summary; PR Newswire 2023
Associate diversification (Megachem Thailand, H1 2026)65% of SPD Biotech (pharma and medical distribution); US$2.5m preferred stake in Kyberlife (lab-equipment marketplace software); MGT Investment Pte Ltd (Singapore holding)H1 2026 FS, Rule 706A
Sustainability reportingSustainability report, TCFD disclosure and GRI index in AR2024. Climate risk added as one of six enterprise risk management components.AR2024

Medium-term targets and guidance

No quantitative medium-term financial targets or guidance are disclosed. The company states there was no forecast or prospect statement previously disclosed to shareholders (H1 2026 FS, Prospects). The only operational targets identified are improving the working-capital cycle (FY2025 results presentation) and the in-house storage ratio cited in broker coverage.

Products & Services

Disclosure limitation. Megachem does not publish a product-by-product catalogue, revenue by product line, principal or brand names, prices, or product launch years in its filings. It discloses its portfolio at the level of industry clusters and applications. The catalogue below is organised at the most granular level the company discloses. Product-level detail that is not disclosed is marked as such and has not been estimated.

Distribution segment: specialty chemicals by industry cluster

ClusterApplication lineDescription (company framing)Target customerLaunch / version yearPricing modelNamed flagship products
Performance Coatings & Polymers (32% of FY2025 sales)Paints and inksAdditives, resins and intermediates for paint and ink formulatorsPaint and ink manufacturers—Transactional resale; price lists not disclosed—
—PolymerisationChemicals used in polymer productionPolymer producers—Transactional—
—AdhesivesRaw materials for adhesive formulationsAdhesive makers—Transactional—
—ConstructionConstruction-chemical inputsConstruction-chemical formulators—Transactional—
—TextilesTextile processing chemicalsTextile mills / processors—Transactional—
Surface Technology (27%)ElectronicsSpecialty chemicals for electronics processingElectronics and semiconductor-related manufacturers—Transactional / VMI—
—Metal finishingPlating and surface-treatment chemicalsMetal finishers—Transactional—
—Industrial cleaningCleaning formulations and inputsIndustrial users—Transactional—
—Water treatmentWater treatment chemicalsUtilities, industrial plants—Transactional—
—Pulp and paperProcess chemicalsPaper mills—Transactional—
Biotech (21%)Food and beveragesFood-grade ingredients and additivesF&B manufacturers—Transactional—
—PharmaceuticalsPharma-grade chemicals and excipientsPharma manufacturers—Transactional—
—Nutraceuticals / cosmeceuticalsActive and functional ingredientsSupplement and personal-care makers—Transactional—
—Agriculture / feedAgrochemical and feed inputsAgri and feed producers—Transactional—
—Flavours and fragrances; homecare; photographySpecialty ingredientsFormulators—Transactional—
Advanced Polymer Composites (12%)Rubber; plastics; polyurethane; polyesterAdditives and intermediates for compounding and composite manufactureRubber, plastics and PU/polyester producers—Transactional—
Resources / Oil & Gas (8%)Mining; oleochemicals; petrochemicals; lubricants and grease; oil field / refineryProcess and performance chemicalsResource and energy companies—Transactional—

Manufacturing segment and value-added services

OfferingDescriptionTarget customerPricing model
Contract manufacturing / custom blendingBlending to customer formulations so customers can outsource non-core production, including MNCs entering Asia without capex (AR2024, "Why Megachem")MNC formulatorsService and toll fees (the bulk of manufacturing revenue)
RepackagingBreaking bulk into smaller packagingSmall and medium customersFee / embedded margin
Filling, packaging, labellingFinishing servicesFormulatorsFee
Proprietary chemical products manufacturingMentioned as a capability in AR2024. The products are not named.——
Vendor-managed inventory and just-in-time deliveryMegachem holds and manages stock near customer sitesKey accounts (MNCs)Embedded in product margin
Technical support via application laboratoriesFormulation and application supportAll customersEmbedded
Lab analysis (third-party profile)Craft.co's profile also lists endothermic and exothermic reaction capability, liquid–solid blending vessels and lab analysis.——

Associate-level offerings (Megachem Thailand group, 36.19% owned)

  • Specialty chemical distribution in Thailand (Megachem Thailand, Megachem Plus, Green Leaf Chemical).

  • Graphite products: Mega Fuji Graphite Ltd. Product detail is not publicly disclosed.

  • Pharmaceutical and medical product distribution, plus hospital and lab design consultancy: SPD Biotech, 65% acquired by Megachem Thailand in H1 2026 for THB1.3m (about S$51,000).

Financial Narrative

Basis. Sources are the company Financial Highlights (AR2024), FY2025 results presentation and H1 2026 FS, which are reported, and S&P Global Market Intelligence standardised statements via StockAnalysis.com, which are standardised. Where the two bases differ, the difference is noted. FY = fiscal year ended 31 December. All values are S$m unless stated.

Income statement

Notes:

  • Revenue CAGR FY2021–FY2025 is −2.7%. FY2020–FY2025 is +3.4%, from FY2020 revenue of S$105.2m (derived).

  • FY2023 gross profit includes S$5.9m of inventory written off in the fire. Adjusted FY2023 gross profit was S$28.5m (FY2024 results presentation).

  • FY2024 other income includes S$9.7m of insurance claims and a S$0.62m gain on sale of a Malaysian property. S&P classifies insurance outside operating income, which is why the S&P operating line is negative in FY2024.

  • FY2024 payout is calculated on adjusted NPAT.

Commentary. The five years contain one up-cycle (FY2021–22), one sharp down-cycle compounded by the fire (FY2023), and a muted recovery with distortions (FY2024–25). The underlying trend in adjusted profit is far weaker than the headline. Adjusted NPAT fell from S$8.0m (FY2021) to S$1.9m (FY2023) and recovered only to S$3.9m (FY2025), even though gross margin is now higher than in FY2021. The difference sits in operating expenses. Staff costs rose from about S$15.5m (FY2023) to S$17.0m (FY2024) and S$16.6m (FY2025). Third-party warehouse storage rose from S$2.7m (FY2023) to about S$3.3–3.4m a year after the fire. Finance costs peaked at S$2.0m in FY2023. The FY2025 gross margin gain to 25.6% came mainly from a lower allowance for inventory impairment, not from pricing (FY2025 results presentation). The inflection is H1 2026: gross margin reached 28.6% on higher chemical prices and an inventory-allowance write-back. EBITDA was S$6.4m in the half alone, close to the S$6.8m for all of FY2025.

Half-year progression: notes and sources

Sources: AR2024 Operating and Financial Review; FY2025 results presentation; H1 2026 FS. H1 2024 gross profit and the H1/H2 2024 EPS split are derived from the reported margins and full-year totals.

Fire incident: profit and loss impact by period

Cumulative to 30 June 2026, insurance income is S$13.667m against S$15.273m of expenses and losses (inventory S$5.919m; PPE S$0.811m; demolition S$3.351m; waste disposal S$3.665m; customer compensation S$0.805m; other S$0.722m). The net cumulative pre-tax hit is about S$1.6m, excluding reconstruction capex. Final insurance recoveries were still under negotiation as of the April 2026 AGM. Source: H1 2026 FS, Review of Performance; 2026 AGM summary.

Balance sheet (as at 31 December)

Sources: S&P via StockAnalysis.com for standardised lines; AR2024 Financial Highlights and FY2025 results presentation for borrowings, gearing and NAV. Latest position (30 June 2026): cash S$14.4m; borrowings S$39.4m (current S$33.2m, non-current S$6.2m); lease liabilities S$3.7m; total equity S$66.8m; NAV per share 48.75 cents; net gearing 0.38x; total assets S$125.8m.

Commentary. The balance sheet is conservative in leverage but heavy in working capital. Inventory peaked at S$49.3m in FY2022 during the restocking cycle and has been run down to S$29.0m. Borrowings are mainly short-term trade finance: bills payable of S$16.2m and short-term loans of S$15.6m at 30 June 2026. This means a high share of debt reprices or rolls within 12 months. The FY2025 step-up in long-term debt (S$6.25m) is the secured construction loan, mortgaged over the 132 Pioneer Road warehouse. PPE nearly doubled in FY2025 as the warehouse was capitalised, with S$14.28m of building cost capitalised by 30 June 2026. There is virtually no goodwill. Book value is tangible.

Cash flow

Source: S&P via StockAnalysis.com. Company-reported OCF matches: S$11.0m (FY2024) and S$5.6m (FY2025). H1 2026 OCF was S$1.3m, after S$3.9m of receivables build. H1 2026 capex was S$4.4m.

Commentary. Cash generation is countercyclical, which is typical of distributors. OCF was negative in the FY2021–22 boom as inventory and receivables ballooned (S$28m of working-capital absorption over two years). It turned strongly positive in the FY2023 destocking. Cumulative FY2021–FY2025 FCF was about −S$1.6m, while dividends paid totalled about S$8.7m. Dividends over the cycle have therefore been funded partly by debt. The FY2025 FCF deficit is almost entirely warehouse capex, which is one-off. With the rebuild largely complete (capital commitments S$2.1m at 30 June 2026), maintenance capex should normalise towards the S$1–3m historical range.

Ratios

Method notes:

  • ROIC = (PBT + finance costs) × (1 − effective tax rate) ÷ (total equity + total debt − cash).

  • EBIT = PBT + finance costs.

  • The FY2023 net debt/EBITDA value is negative because EBITDA was negative. It is not meaningful.

  • FY2024 ROE, ROA and ROIC are inflated by S$9.7m of insurance income.

  • The FY2021–FY2024 ROE values match the company-reported figures.

Company-reported working-capital turnover days

The company's day counts are higher than the year-end derived ones, likely because the company uses average balances or balances gross of allowance. The method is not disclosed. Both bases show a cash cycle of more than five months. H1 2026 company figures: inventory 140 days, receivables 72 days, payables 24 days. Management has stated a target to improve the working-capital cycle (FY2025 results presentation).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsProducts / services

Distribution

Trading of more than 1,000 specialty chemical types and grades across all subsidiaries

Specialty chemical resale, VMI, JIT delivery, technical support

Manufacturing

Contract manufacturing and custom blending, principally in Singapore (Megachem Manufacturing Pte Ltd)

Blending to customer formulations, repacking, filling, labelling. Revenue is mainly service fees.

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2023FY2024FY2025

Distribution revenue (SGD Mn)

119.298124.920121.139

Manufacturing revenue (SGD Mn)

3.7113.9223.273

Total revenue (SGD Mn)

123.009128.842124.412

Distribution % of total

97.097.097.4

Manufacturing % of total

3.03.02.6

Distribution YoY growth (%)

-14.44.7-3.0

Manufacturing YoY growth (%)

-14.25.7-16.5

Revenue by Segment

MetricH1 2025H2 2025H1 2026

Distribution revenue (SGD Mn)

62.32858.81164.176

Manufacturing revenue (SGD Mn)

1.7451.5281.678

Distribution segment result (SGD Mn)

1.9492.04.227

Manufacturing segment result (SGD Mn)

0.0250.10.401

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment — Singapore

MetricH1 2025H1 2026

Singapore (SGD Mn)

24.28425.334

Malaysia (SGD Mn)

7.1365.854

United Kingdom (SGD Mn)

9.31910.292

China (SGD Mn)

6.8277.017

Middle East (SGD Mn)

6.4347.300

Others (SGD Mn)

10.07310.057

Total (SGD Mn)

64.07365.854

Group Entities

EntityCountryFunctionGroup interest

Megachem Limited

Singapore

Parent; distribution; HQ

—

Megachem Manufacturing Pte Ltd

Singapore

Contract manufacturing / blending

—

Megachem Raya Pte Ltd and subsidiary

Singapore

Distribution

83% (since Nov 2024; previously 74%)

Megachem (Shanghai) Pte Ltd

Singapore

Holding for China

—

Megachem International Trading (Shanghai) Co., Ltd

China

Distribution

—

Megachem International Trading (Beijing) Co., Ltd

China

Sales office

—

C.N. Chemicals Sdn Bhd

Malaysia

Distribution / warehousing

100% (wholly owned per AR2024)

P.T. Mega Kemiraya

Indonesia

Distribution

—

Megachem Phils., Inc

Philippines

Distribution

—

Megachem Vietnam Company Limited

Vietnam

Distribution

—

Megachem (Myanmar) Limited

Myanmar

Distribution

—

Megachem Specialty Chemicals (I) Private Limited

India

Distribution

Not publicly disclosed. Negative net tangible assets; parent provides financial support (S$0.905m undertaking at 30 Jun 2026).

Megachem Middle East FZE

UAE (Jebel Ali Free Zone)

Distribution

—

Megachem (UK) Ltd

United Kingdom

Distribution (Europe)

97% (since Mar 2024; previously 85%)

Megachem Australia Pty Ltd (formerly MG Chemicals (Australia) Pty Ltd)

Australia

Distribution

Not publicly disclosed. Negative net tangible assets; parent support undertaking S$1.159m.

Megachem Plus Limited

Thailand

Distribution

—

Megachem (Thailand) PCL (SET: MGT)

Thailand

Distribution; associate

36.19% (associate, equity-accounted)

Green Leaf Chemical Co., Ltd; Mega Fuji Graphite Ltd; SPD Biotech Co., Ltd (65%, acquired H1 2026); MGT Investment Pte Ltd

Thailand / Singapore

Subsidiaries of Megachem Thailand

Indirect, via the 36.19% associate (SPD about 23.52% indirect; MGT Investment about 36.19% indirect)

“—” = not publicly disclosed.

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (SGD Mn)

138.90143.72123.01128.84124.41

Revenue growth YoY (%)

32.03.5-14.44.7-3.4

Cost of sales (SGD Mn)

104.79109.31100.5197.6192.61

Gross profit (SGD Mn)

34.1134.4122.5031.2331.80

Gross margin (%)

24.623.918.324.225.6

Operating income, S&P standardised, excl. insurance and other income (SGD Mn)

7.257.13-8.15-1.293.98

Operating margin, S&P basis (%)

5.25.0-6.6-1.03.2

EBITDA, company-reported (SGD Mn)

11.110.5-1.911.86.8

EBITDA margin (%)

8.07.3-1.59.25.5

Finance costs (SGD Mn)

0.801.382.041.911.41

Share of associates' profit (SGD Mn)

1.611.121.171.221.17

Profit before tax (SGD Mn)

9.197.83-5.348.694.27

Income tax (SGD Mn)

1.201.760.460.780.36

Net profit after tax, group (SGD Mn)

8.06.1-5.87.93.9

Net profit attributable to equity holders (SGD Mn)

7.765.88-5.917.913.83

Adjusted NPAT excl. fire impact (SGD Mn)

8.06.11.92.93.9

Net margin, attributable (%)

5.64.1-4.86.13.1

EPS basic = diluted (S cents)

5.824.41-4.435.932.88

Dividend per share (S cents)

2.02.00.01.01.0

Dividend payout, company basis (%)

34.445.40.046.034.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%) (Half-Yearly)

MetricH1 2024H2 2024H1 2025H2 2025H1 2026

Sales (SGD Mn)

65.263.764.160.365.9

Gross profit (SGD Mn)

15.515.716.115.718.8

Gross margin (%)

23.824.725.126.128.6

EBITDA (SGD Mn)

4.57.33.43.46.4

NPAT (SGD Mn)

2.05.91.72.24.6

Adjusted NPAT excl. fire (SGD Mn)

1.71.31.72.23.4

EPS (S cents)

1.504.431.261.613.42

Key Financials

MetricH2 2023H1 2024H2 2024H1 2025H2 2025H1 2026

Insurance claims income (SGD K)

3,1494,9104,408001,200

Total fire-related expenses / losses (SGD K)

-10,887-4,188-198000

Net impact before tax (SGD K)

-7,7387224,210001,200

Balance Sheet and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (SGD Mn)

110.93117.09100.24104.53115.01

Cash and short-term investments (SGD Mn)

12.0811.9313.6315.9714.01

Inventories (SGD Mn)

36.4549.3433.5631.7429.04

Trade receivables (SGD Mn)

30.5827.0322.9822.8723.57

Property, plant and equipment incl. right-of-use (SGD Mn)

18.0217.9516.9819.1632.71

Investments in associates and other LT investments (SGD Mn)

7.977.909.7410.7011.58

Goodwill and intangibles (SGD Mn)

0.030.030.020.030.03

Bank borrowings excl. leases, company-reported (SGD Mn)

28.936.428.525.234.7

Short-term debt incl. current leases (SGD Mn)

27.9035.7628.3225.6028.76

Long-term debt incl. non-current leases (SGD Mn)

4.003.323.072.758.95

Total debt incl. leases (SGD Mn)

31.8939.0931.3928.3537.71

Net debt incl. leases (SGD Mn)

19.8127.1517.7612.3823.71

Equity attributable to owners (SGD Mn)

57.2658.5949.9658.5561.31

Non-controlling interests (SGD Mn)

3.133.153.201.951.75

Total equity (SGD Mn)

60.3961.7453.1660.4963.06

Working capital (SGD Mn)

37.6638.9429.0432.8327.24

NAV per share (S cents)

42.9543.9637.4843.9246.00

Gearing, company basis (x)

0.510.620.570.430.57

Net gearing, company basis (x)

0.300.420.300.160.34

Cash Flow and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (SGD Mn)

-7.86-2.9715.8211.055.65

Change in working capital (SGD Mn)

-16.38-11.9510.55-0.13-0.06

Capital expenditure (SGD Mn)

-3.42-1.66-1.19-2.74-14.24

Free cash flow (SGD Mn)

-11.29-4.6414.648.31-8.59

Free cash flow margin (%)

-8.1-3.211.96.5-6.9

Dividends paid to equity holders (SGD Mn)

-2.40-2.67-1.60-0.67-1.33

Share buybacks (SGD Mn)

00000

Net debt issued / (repaid) (SGD Mn)

8.846.95-8.07-3.829.62

Cash interest paid (SGD Mn)

0.641.051.941.771.27

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2021FY2022FY2023FY2024FY2025

ROE, attributable NPAT / year-end equity (%)

13.610.0-11.813.56.2

ROA, attributable NPAT / total assets (%)

7.05.0-5.97.63.3

ROIC, derived (%)

10.88.0-4.713.26.0

Current ratio (x)

1.811.751.671.801.64

Debt / equity incl. leases (x)

0.530.630.590.470.60

Net debt / EBITDA (x)

1.782.59-9.351.053.49

Interest coverage, EBIT / finance costs (x)

12.56.7-1.65.54.0

Asset turnover, revenue / total assets (x)

1.251.231.231.231.08

Inventory days, year-end inventory / COGS × 365 (derived)

127165122119114

Receivable days, year-end AR / revenue × 365 (derived)

8069686569

Payable days, year-end AP / COGS × 365 (derived)

2923262424

Cash conversion cycle, derived (days)

178211164160159

Working Capital (Days)

MetricFY2023FY2024FY2025

Inventory turnover (days)

170147147

Trade receivables turnover (days)

766669

Trade payables turnover (days)

352726

Cash conversion cycle, derived from company days

211186190

Revenue by Region

MetricFY2023FY2024FY2025

ASEAN (SGD Mn)

72.22674.25268.123

Europe (SGD Mn)

15.70416.28416.100

North Asia (SGD Mn)

10.31612.45115.875

Middle East (SGD Mn)

10.55910.98711.571

Australia (SGD Mn)

9.69210.2168.464

South Asia (SGD Mn)

3.8204.2463.764

America (SGD Mn)

0.2120.1660.258

Africa (SGD Mn)

0.4800.2400.257

Total (SGD Mn)

123.009128.842124.412

Geographic Revenue

MetricFY2024 YoY (%)FY2025 YoY (%)FY2025 share (%)

ASEAN

2.8-8.354.8

Europe

3.7-1.112.9

North Asia

20.727.512.8

Middle East

4.15.39.3

Australia

5.4-17.16.8

South Asia

11.2-11.43.0

America

-21.755.40.2

Africa

-50.07.10.2

Geographic Revenue (Half-Yearly)

MetricH1 2025H2 2025H1 2026

ASEAN

35,59432,52936,126

Europe

8,4877,6139,249

North Asia

7,7848,0917,469

Middle East

6,3885,1837,031

Australia

3,7224,7423,769

South Asia

1,7691,9951,626

America

20949257

Africa

120137327

Total

64,07360,33965,854

Share Price History

DatePriceSource

17 Oct 2003 (IPO)

0.280

Company

30 Jun 2024

0.470

H1 2024 presentation (yield calculation)

31 Dec 2024

0.430

AR2024 (yield calculation)

19 Feb 2025

0.395

AR2024

8 Sep 2025

0.450

GuruFocus dividend event log

31 Dec 2025

0.420

FY2025 presentation (yield calculation)

23 Feb 2026

0.420

FY2025 presentation

6 Jul 2026

0.490

StockAnalysis.com

4 Sep 2026

0.490

StockAnalysis.com

5 Oct 2026

0.450

StockAnalysis.com

Valuation Multiples

MultipleMegachemBasis

Market capitalisation

S$60.0m

133.3m shares

Enterprise value

about S$90.5m

Market cap + borrowings S$39.4m + leases S$3.7m + NCI S$1.8m − cash S$14.4m (30 Jun 2026)

P/E, trailing 12 months reported

8.9x

TTM EPS 5.03 cents (H2 2025 1.61 + H1 2026 3.42)

P/E, TTM excluding insurance

about 10.9x

TTM adjusted EPS about 4.13 cents

P/E, FY2025

15.6x

FY2025 EPS 2.88 cents

EV/EBITDA, TTM

9.2x

TTM EBITDA S$9.8m (H2 2025 3.4 + H1 2026 6.4)

EV/EBITDA, TTM excluding insurance

about 10.5x

Adjusted TTM EBITDA about S$8.6m

EV/Sales, TTM

0.72x

TTM sales S$126.2m (GuruFocus shows 0.73x)

P/B

0.92x

NAV 48.75 cents (30 Jun 2026)

Dividend yield, trailing

2.2%

1.0 cent over the last 12 months

Analyst Ratings & Targets

BrokerDateRatingTarget price

SAC Advisors / SAC Capital

Jun 2018

Buy (initiation)

50 cents

SAC Capital

Aug 2021

Buy

55 cents

SAC Capital

Jun–Aug 2022

Buy

58 cents

SAC Capital

Aug 2025

Hold

50 cents (from 39 cents)

Per-Share Data

MetricFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Dividend per share (S cents)

1.201.201.501.501.502.002.000.001.001.00

Bucket Details

BucketSGD MnDetail

Within 12 months

33.19

Bills payable S$16.21m; short-term loans S$15.63m (S$3.0m secured); current portion of long-term loans S$1.00m (secured); overdraft S$0.34m

After 12 months

6.18

Long-term loans: S$5.75m secured on the warehouse; S$0.43m unsecured

Lease liabilities

3.68

Current S$0.50m; non-current S$3.18m

Total borrowings excluding leases

39.37—

Analyst Conclusions

Management guidance

  • No numerical guidance. The H1 2026 prospects statement expects the global outlook for H2 2026 to remain fragile, with Middle East tensions weighing. It expects moderate growth supported by AI and technology sectors, and continuing chemical-industry pressure from volatile feedstock prices and supply-chain disruption.

  • Megachem plans to:

    • stay focused on specialty chemicals for margin stability;

    • capture significant warehousing cost savings from the new facility;

    • maintain prudent inventory and financial management.

Consensus expectations

  • None available.

  • Stockopedia lists FY2026E and FY2027E columns, but the underlying estimates were not visible.

Bull case

  1. Structural cost tailwind. Third-party storage of S$3.3–3.4m a year should fall sharply from H2 2026 now that inventory has moved back into the owned warehouse. That alone could add up to about S$2m a year to EBITDA (derived; partly offset by about S$0.4–0.5m of extra depreciation each half). On top of H1 2026's adjusted NPAT of S$3.4m, FY2026 adjusted NPAT of about S$6–7m (EPS about 4.5–5.3 cents) looks plausible. At that level the stock would trade at about 9–10x.

  2. Margin regime change. Gross margin has risen for five consecutive halves, from 23.8% to 28.6%. The rise came from mix (Biotech plus Surface Technology are 48% of sales) and from higher prices, not only one-offs.

  3. Asset backing plus optionality. The stock trades at 0.92x NAV, and that NAV includes a newly built Singapore hazardous-goods warehouse at cost. Further optionality comes from unsettled insurance recoveries, the JIOS Aerogel stake, and the 36.19% Thai associate. The SET-listed associate's market cap of about THB676–784m implies a look-through value of roughly S$9–11m at prevailing THB rates. This is approximate and FX-dependent.

Bear case

  1. Revenue has not grown. FY2025 revenue is 13% below FY2022 and below FY2021, and the five-year CAGR is negative. The core ASEAN market fell 8.3% in FY2025. Cost savings cannot compound if the top line is stuck.

  2. Cash generation is weak and debt is short-dated. Cumulative five-year FCF is negative. Borrowings have risen to S$39.4m (net gearing 0.38x), 84% due within 12 months. H1 2026 OCF of S$1.3m on S$5.0m of PBT shows how working capital absorbs profits in any upturn.

  3. Governance and liquidity discount is likely to persist. About two-thirds of shares are held by the MD and Chori. Dissent ran at 22–34% at the 2026 AGM. Dividends were cut from 2.0 cents (FY2022) to 1.0 cent despite shareholder pushback. The only research comes from the sponsor, so the stock has few natural re-rating catalysts.

Catalysts and things to monitor (next 12 months)

FY2026 results (around Feb 2027): the first full half of in-house warehousing (H2 2026), and whether warehouse storage charges, about S$1.6m a half, fall materially.

Final insurance settlement: whether further recoveries are announced.

Gross margin durability above 27%: as H1 2026 price support fades.

Middle East and Europe momentum: versus Gulf-conflict disruption.

  • Inventory days (target below 140) and receivable days (72 in H1 2026), to see whether OCF recovers.

Any change in Chori's stake or in the co-founder's 19% block: A block sale or a take-private would be the largest potential re-rating event.

FY2026 dividend: whether it returns towards 1.5–2.0 cents.

Status of the former executive director's claims: - Further insider buying by the MD, following the Sep 2026 filings.

Concluding analyst verdict

Megachem is a well-run but structurally sub-scale specialty chemicals distributor. Its investment case for the next 12–18 months rests more on cost normalisation than on growth. The July 2023 fire distorted three years of reported earnings: a S$5.8m loss in FY2023, a S$7.9m insurance-inflated profit in FY2024, and a S$3.9m profit in FY2025 weighed down by stopgap warehousing costs. With the Pioneer Road warehouse operating from June 2026, H1 2026 gives the clearest view so far of underlying earnings power. Adjusted NPAT was S$3.4m in a single half, EBITDA was S$6.4m and gross margin was 28.6%, all better than any half since 2022.

Against that, the top line is the weak point. Revenue of S$124m sits within a band the company first reached a decade ago. ASEAN, more than half of sales, contracted in FY2025. Parent-level M&A over five years amounted to minority buy-outs. Larger rivals such as Brenntag, IMCD and Azelis earn EBITDA margins about 1.5–2.3 times higher and are consolidating principal mandates across Asia, which is a slow-moving threat to an unnamed-principal model.

The balance sheet is sound on gearing but not on duration. Most debt is trade finance rolling within a year, and working capital absorbs cash whenever sales grow. Governance is orderly, with an independent chairman and a refreshed board, but control is concentrated. Dissent at the 2026 AGM points to unresolved friction with part of the shareholder base.

At S$0.45 the shares trade at about 0.9x NAV, about 11x trailing adjusted earnings and about 10x adjusted EV/EBITDA. That leaves room for upside if warehouse savings take adjusted FY2026 earnings towards 5 cents per share. It offers little protection if chemical pricing softens again. The overall stance is neutral with a positive operational bias. The key evidence will be the H2 2026 cost line and FY2026 operating cash flow.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedAge (per AR2024, early 2025)EducationPrior / other roles

Yeo Wee Kiong

Independent and Non-Executive Chairman; Chair of Nominating Committee; member of Audit and Remuneration Committees

20 Apr 2024

69

Barrister-at-Law (Lincoln's Inn); MBA (NUS); LLB Hons (London); B.Eng Mech Hons (NUS)

Directorships at AF Global, Pacific Century Regional Development, SUTL Enterprise; past boards include Roxy-Pacific, Asian Healthcare Specialists

Sidney Chew Choon Tee

Managing Director (the CEO-equivalent); Chair of Executive Committee; member of Nominating Committee

Director since 28 Apr 1989; MD since 9 Nov 2005

64

B.Sc Chemistry (Hons); BA Business Administration

Co-founder. Executive Chairman until 1 Mar 2020. Director of Megachem Thailand PCL and most subsidiaries. Re-elected 28 Apr 2026.

Sim Guan Seng

Independent Director; Chair of Audit Committee; member of Nominating and Remuneration Committees

20 Apr 2024

65

B.Acc Hons (NUS); FCCA; Certified Internal Auditor

MD of Cohen Assurance PAC since 2022; partner at Baker Tilly TFW 2004–2022; boards of Darco Water Technologies and Sitra Holdings

Daniel Loh Hong Chye

Independent Director; Chair of Remuneration Committee; member of Audit Committee

20 Apr 2024

58

MBA (Oklahoma City University); B.Eng Mech (NUS)

MD and President Chemicals Asia, HELM Asia (Aug 2019–May 2023); President Director, BASF Indonesia; MD, BASF Malaysia

Yasutaka Kawamura

Non-Executive, Non-Independent Director (Chori nominee)

1 Jul 2020

54

MBA; B.Econ

Executive Officer and Deputy GM, Corporate Planning, Chori Co., Ltd; President, Chori Machinery. Re-elected 28 Apr 2026.

Executive Leadership Team

NameTitleTenureBackground

Sidney Chew Choon Tee

Managing Director

Co-founder, 1988

See above

Francis Yau Thiam Hwa

Chief Financial Officer

Joined 2000; CFO since 1 Jan 2007

Former corporate banker; BBA (Finance) NUS; ISCA member. Independent director of one other SGX-listed company.

Kwok Hwee Peng

Group Finance Manager and Company Secretary

Joined 2002; GFM since 2008

Ex-PricewaterhouseCoopers; B.Acc NTU; ISCA member

Peck Jen Jen

Joint Company Secretary

Since 15 Aug 2024

—

Board & Management Changes

DateChange

1 Mar 2019

Yokogawa (Chori) resigns; Sakoda (Chori) appointed

1 Mar 2020

Chew steps down as Executive Chairman; Lee Bon Leong becomes Independent Chairman

1 Jul 2020

Kawamura (Chori) appointed

19 Apr 2023

Co-founder Tan Bock Chia retires from the board

19–20 Apr 2024

Lee Bon Leong, Chan Kam Loon and Tay Kin Bee retire; Yeo, Sim and Loh appointed

15 Aug 2024

Peck Jen Jen replaces Hon Wei Ling as Joint Company Secretary

28 Apr 2026

Chew and Kawamura re-elected, each with 22.32% of votes cast against

Major Shareholders

HolderShares% of 133.3mAs at / source

Sidney Chew Choon Tee (direct and deemed)

48,267,01236.21

10 Mar 2025 (AR2024). Further purchases filed Sep 2026; updated total not captured.

Chori Co., Ltd (held via custodian / nominee)

39,976,67029.99

AGM results 2018–2024; AR2024

Tan Bock Chia (co-founder, former director)

25,435,08319.08—

Implied free float (residual)

about 19,600,000

about 14.7

Derived, if the Tan holding is unchanged

Competitive Landscape

Key Competitors

CompetitorTypeOverlap with MegachemScale indicatorRelative positioning

Brenntag SE (Germany)

Global #1 chemical distributor

All clusters; strong in APAC

FY2025 sales €15.2bn; operating EBITDA €1.29bn (8.5% margin)

Roughly 100x Megachem's revenue; full-line industrial plus specialties

IMCD N.V. (Netherlands)

Global specialty distributor

Coatings, pharma, food, personal care in APAC

FY2025 operating EBITA €498m (−6%). Revenue rose slightly versus FY2024; the exact FY2025 figure was not captured.

Asset-light, M&A-driven; seven acquisitions in 2025, including in Korea and China

Azelis Group (Belgium)

Global specialty distributor

Life sciences, coatings and industrial in APAC

FY2025 revenue €4.1bn; adjusted EBITDA €239m (12.8% margin)

Specialty-focused, roughly double Megachem's EBITDA margin

Univar Solutions (US; private since 2023)

Global distributor

Industrial and specialty in APAC

—

Large full-line competitor

DKSH (Switzerland), Performance Materials unit

Market-expansion services

Specialty chemicals in ASEAN

—

Strong ASEAN footprint

Nagase & Co. (Japan)

Japanese chemical trading house

Specialty chemicals in Asia

—

Japanese principal relationships

Connell Bros. (Wilbur-Ellis group)

Asia-Pacific specialty distributor

Coatings, food and personal care in ASEAN

Not publicly disclosed (private)

Direct regional peer

Behn Meyer (Germany/Asia)

SE Asia specialty distributor

Coatings, polymers and agri in ASEAN

Not publicly disclosed (private)

Direct regional peer

Jebsen & Jessen Chemicals

Asian distributor

Industrial and specialty chemicals in SE Asia

Not publicly disclosed (private)

Regional peer

HELM AG / HELM Asia (Germany)

Chemical marketing and distribution

Industrial chemicals in Asia

—

Independent director Daniel Loh previously led HELM Asia

Redox Limited (Australia)

Chemical distributor

Australia and Asia

—

Competes in Australia, where Megachem's sales fell 17.1% in FY2025

Chori Co., Ltd (Japan)

Trading house

Chemicals trading

—

Shareholder and partner, and a potential competitor

“—” = not publicly disclosed.

Peer Comparison FY2025

MetricMegachemBrenntagAzelisIMCD

Revenue

S$124.4m

€15.2bn

€4.1bn

Not captured (slight increase reported)

Revenue growth (reported currency)

-3.4%-3.7%-2.4%

Slight increase; −3% FX impact

EBITDA margin

5.5%

8.5% (operating EBITDA)

12.8% (adjusted EBITDA)

Not captured (EBITA €498m)

Gross margin

25.6%

Not captured

Not captured

Not captured

R&D intensity

Not disclosed (nil reported)

———

Acquisitions in 2025

None at parent level

Not captured

4 (prior-year revenue over €110m)

7

“—” = not publicly disclosed.

Company Snapshot

$95M

Revenue

258

Employees

1988

Founded

Singapore

Headquarters

SWOT Analysis

Strengths

  • A diversified, sticky customer base: more than 2,000 industrial customers, mostly MNCs, with management stating no significant credit-risk concentration (H1 2026 FS, Risks).
  • Resilience through cycles: a profit in every year except one in the past 10. GuruFocus counts 9 profitable years out of 10, and FY2023 was the first loss since the 2003 listing (FY2023 news release).
  • Gross margin at a high: 28.6% in H1 2026, versus 23.9% in FY2022 and 25.6% in FY2025.
  • Owned hazardous-goods infrastructure: the rebuilt MHI-compliant warehouse (budget about S$19m; capacity of more than 5,000 pallets) reduces dependence on scarce third-party chemical storage.
  • Conservative balance sheet: net gearing of 0.16–0.42x over FY2020–FY2025, almost no goodwill, and an NAV of 48.75 cents above the S$0.45 share price.
  • Stable, aligned leadership: the MD owns about 36% and bought shares in Sep 2026. The CFO has been in post since 2007. Governance awards include Best Managed Board Gold (2015) and Bronze (2018).

Weaknesses

  • Thin profitability: EBITDA margin of 5.5% in FY2025, against 8.5% at Brenntag and 12.8% at Azelis.
  • Working-capital intensity: cash conversion cycle of 159–211 days (derived) and inventory days of 140–170 (company). Five-year cumulative FCF is negative (about −S$1.6m).
  • Revenue stagnation: FY2021–FY2025 revenue CAGR of −2.7%. FY2025 revenue (S$124.4m) is below FY2014 (S$115.9m) plus inflation, in real terms.
  • Loss-making or weak subsidiaries: Australia and India have negative NTA, and India is mostly loss-making (2026 AGM). The parent's support undertakings total S$2.06m.
  • Short-dated debt profile: 84% of borrowings were current at 30 Jun 2026 (S$33.2m of S$39.4m).
  • Illiquid, tightly held stock: the free float is roughly 15% if the co-founder's 19% stake is unchanged. Only one sell-side house covers the stock, and it is also the company's sponsor.

Opportunities

  • Warehouse cost savings: third-party storage cost about S$3.3–3.4m a year in FY2024–25. Even a 50% saving would be worth about 1.3–1.4 percentage points of EBITDA margin (derived).
  • ASEAN manufacturing relocation: Malaysia, Indonesia and Vietnam are named growth markets, where Megachem already has offices.
  • Growth in North Asia and the Middle East: North Asia +27.5% and Middle East +5.3% in FY2025; Middle East +10.1% in H1 2026.
  • High-growth industries: EV, electronics and life-science specialty chemicals, plus an option value on JIOS Aerogel's thermal-blade supply contract.
  • Final insurance settlement: S$13.7m received so far, with negotiations ongoing. Any further recovery would be one-off income.
  • Bolt-on M&A or principal wins: a 100% share-issue mandate and associate-level deal activity (SPD Biotech, Kyberlife) show some appetite for deals.

Threats

  • Chemical oversupply and price deflation: cited as the cause of weak FY2025 demand and pricing.
  • Trade policy shocks: US tariffs disrupted customer planning in H2 2025.
  • Gulf conflict: the Middle East is 9.3% of sales and the most profitable overseas segment, and energy prices feed chemical costs (H1 2026 Risks).
  • Principal disintermediation: global distributors consolidating principal mandates. Loss of a core distributorship is a stated risk.
  • Operational hazard recurrence: the 2023 fire cost S$15.3m in gross losses and expenses, and insurance premiums rose 15.2% in FY2025.
  • Governance friction: 22–34% dissent at the 2026 AGM, and a former executive director's profit-sharing claims are unresolved.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
22 Apr 2025 (scheduled per AR2024 financial calendar)AGM for FY2024; final dividend of 0.5 cent approvedTotal FY2024 dividend of 1.0 cent, versus nil for FY2023
H1 2025Customers frontload inventory in response to US tariffsSupported H1 2025 sales; created payback in H2
13 Aug 2025H1 2025 results: revenue −1.7% to S$64.1m; NPAT −15.8% to S$1.68m; gross margin up to 25.1%; interim dividend 0.5 centMargin improvement despite weaker volume
Aug 2025SAC Capital keeps "hold" and raises target price from 39 to 50 cents (30% discount to a peer mean forward P/E of 21.8x)Only sell-side coverage identified, and it comes from the company's own sponsor
8 Sep 2025 (ex-date)Interim FY2025 dividend of 0.5 centDividend continuity
H2 2025US tariffs complicate customers' production and inventory planning; industry oversupply keeps prices softH2 2025 sales of S$60.3m, the weakest half since H1 2023
Late 2025Warehouse construction nears completion; target pushed from end-2025 to an operational target of end-March 2026Slight schedule slippage
Late Feb 2026 (filing dated 25 Feb 2026)FY2025 results: revenue S$124.4m (−3.4%); NPAT S$3.9m (−50.6%); adjusted NPAT +31.1%; final dividend 0.5 centBase year after the fire; operating costs down S$1.1m on an adjusted basis
Feb 2026FY2025 results presentation sets out the "Unlocking our Potential" growth pillarsStrategic framing for FY2026
Feb 2026MD describes FY2025 as challenging, citing oversupply and trade complexityTone check
28 Apr 2026AGM: all eight resolutions passed; about 22% against FS adoption, both re-elections and the share-issue mandate; 34% against the IPT mandateSignals a sizeable dissenting minority
28 Apr 2026AGM disclosure: insurance proceeds of S$13.7m received; final recoveries still under negotiationPossible further one-off income
28 Apr 2026AGM disclosure: JIOS Aerogel investment details, including preference shares and the automaker supply contractTransparency on the strategic investment
28 Apr 2026AGM disclosure: Australian and Indian subsidiaries have negative NTA; India mostly loss-makingIdentifies weak spots
28 Apr 2026AGM: shareholders press for higher dividends (below 2 cents seen as unattractive); a former executive director's profit-sharing claims are acknowledged and private discussion is offeredGovernance and capital-allocation friction
H1 2026Megachem Thailand acquires 65% of SPD BiotechAssociate-level diversification into healthcare distribution
H1 2026Megachem Thailand and Green Leaf invest US$2.5m in KyberlifeAssociate-level venture investment
H1 2026Megachem Thailand incorporates MGT Investment Pte Ltd in SingaporeAssociate builds a Singapore holding vehicle
~8 Jun 2026 (ex-date)Final FY2025 dividend of 0.5 cent—
Jun 2026Warehouse Temporary Occupation Permit; major part of inventory moved back from third-party warehousesKey operational milestone and cost catalyst
H1 2026Insurance compensation of S$1.25m recognised in other incomeOne-off support to H1 2026 profit
H1 2026Gulf ceasefire instability lifts energy prices; management flags supply and energy-price riskNew macro risk vector, especially for Middle East sales
6 Aug 2026Notice of H1 2026 results dateRoutine
13 Aug 2026H1 2026 results: revenue +2.8% to S$65.9m; gross margin 28.6%; NPAT +167.9% to S$4.6m; adjusted NPAT S$3.4m (doubled); EBITDA S$6.4mBest half-year profitability since H1 2022
13 Aug 2026Borrowings rise to S$39.4m; net gearing 0.38xWorking-capital build and warehouse funding
13 Aug 2026Interim dividend of 0.5 cent declared; record date 10 Sep, paid 30 Sep 2026Dividend maintained, not raised
2, 18 and 24 Sep 2026MD Chew Choon Tee files director-dealing disclosures for share acquisitionsInsider buying after the strong H1
5 Oct 2026Shares close at S$0.45, after S$0.49 on 4 Sep 2026Gave back part of the post-results rally

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Revenue fell from SGD 138.9 Mn in FY2021 to SGD 124.4 Mn in FY2025.
Megachem Limited — Income Statement: Revenue & Gross Profit
Series (SGD Mn)FY2021FY2022FY2023FY2024FY2025
Revenue138.9143.7123128.8124.4
Cost of sales104.8109.3100.597.692.6
Gross profit34.134.422.531.231.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. [Megachem News Release H1 2026 (SGX, 13 Aug 2026)]( (links.sgx.com)
  2. [Megachem Condensed Interim Financial Statements H1 2026 (SGX, 13 Aug 2026)]( (links.sgx.com)
  3. [Megachem Results Announcement Date H1 2026 (SGX, 6 Aug 2026)]( (links.sgx.com)
  4. [Megachem Results Presentation FY2025 (SGX)]( (links.sgx.com)
  5. [Megachem Annual Report 2024 (SGX)]( (links.sgx.com)
  6. [Megachem News Release FY2024 (SGX, 20 Feb 2025)]( (links.sgx.com)
  7. [Megachem Results Presentation FY2024 (SGX)]( (links.sgx.com)
  8. [Megachem News Release FY2023 (SGX, 21 Feb 2024)]( (links.sgx.com)
  9. [Megachem Results Presentation FY2023 (SGX)]( (links.sgx.com)
  10. [Megachem News Release FY2022 (SGX)]( (links.sgx.com)
  11. [Megachem News Release H1 2024 (SGX)]( (links.sgx.com)
  12. [Megachem Results Presentation H1 2024 (SGX)]( (links.sgx.com)
  13. [Megachem News Release H1 2023 (SGX)]( (links.sgx.com)
  14. [Megachem News Release H1 2022 (SGX)]( (links.sgx.com)
  15. [Change of Directors and Board Committees, Apr 2024 (SGX)]( (links.sgx.com)
  16. [Cessation of Tan Bock Chia (SGX, 2023)]( (links.sgx.com)
  17. [Appointment of Independent Director Daniel Loh (SGX)]( (links.sgx.com)
  18. [Appointment of Independent Director Sim Guan Seng (SGX)]( (links.sgx.com)
  19. [Results of AGM, 18 Apr 2022 (SGX)]( (links.sgx.com)
  20. [Results of AGM, 19 Apr 2024 (SGX)]( (links.sgx.com)
  21. [Resignation and Appointment of Non-Executive Director, Mar 2019 (SGX)]( (links.sgx.com)
  22. [Megachem 2026 AGM Minutes Summary (Minichart, 20 May 2026)]( (minichart.com.sg)
  23. [Megachem Income Statement (StockAnalysis.com / S&P Global)]( (stockanalysis.com)
  24. [Megachem Balance Sheet (StockAnalysis.com / S&P Global)]( (stockanalysis.com)
  25. [Megachem Cash Flow Statement (StockAnalysis.com / S&P Global)]( (stockanalysis.com)
  26. [Megachem Ltd profile (GuruFocus)]( (gurufocus.com)
  27. [MegaChem share price page (Stockopedia)]( (stockopedia.com)
  28. [Megachem management (Simply Wall St)]( (simplywall.st)
  29. [Megachem filings index (FinancialFilings.com)]( (financialfilings.com)
  30. [MegaChem company profile (Craft.co)]( (craft.co)
  31. [Megachem's FY2025 earnings down on softer demand (The Edge Singapore)]( (testing.dev.theedgesingapore.com)
  32. [SAC Capital stays 'hold' on Megachem, TP 50 cents (The Edge Singapore)]( (testing.dev.theedgesingapore.com)
  33. [SAC Advisors initiates Megachem at 'buy' (The Edge Singapore, 2018)]( (testing.dev.theedgesingapore.com)
  34. [SAC lifts Megachem TP to 55 cents (The Edge Singapore, 2021)]( (alfi.dev.theedgesingapore.com)
  35. [Megachem kept at 'buy' on 1H earnings beat (The Edge Singapore, 2022)]( (alfi.dev.theedgesingapore.com)
  36. [Founders of Megachem raise stakes (The Edge Malaysia, 2014)]( (theedgemalaysia.com)
  37. [JIOS Aerogel secures investment from MegaChem (Macau Business / PR Newswire, Sep 2023)]( (macaubusiness.com)
  38. [Megachem (Thailand) PCL profile (Simply Wall St)]( (simplywall.st)
  39. [Megachem Thailand PCL (Google Finance)]( (google.com)
  40. [Brenntag full-year 2025 results]( (brenntag.com)
  41. [Azelis full-year 2025 results]( (azelis.com)
  42. [IMCD 2025 results coverage (European Coatings)]( (european-coatings.com)
  43. [Chemical distribution market estimate (SNS Insider)]( (snsinsider.com)
  44. [Chemical distribution market estimate (Polaris Market Research)]( (polarismarketresearch.com)
  45. [Chemical distribution market estimate (Global Market Insights)]( (gminsights.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.